SCHEMBL2212833

SCHEMBL2212833

Cc1c2c(=O)n(-c3ccccc3)[nH]c2cc(=O)n1Cc1ccccc1CN1CCOCC1

nearest known ligand 0.61

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
NOX4 Q9NPH5 19/20 0.61
CYBB P04839 2/20 0.56
CYP3A4 P08684 1/20 0.43
NOX1 Q9Y5S8 1/20 0.43
CYP2A13 Q16696 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1302625 0.92 NOX4 (0.55) NOX4CYBBCYP3A4NOX1
SCHEMBL13394146 0.91 NOX4 (0.51) NOX4CYBBCYP3A4NOX1CYP2A13
SCHEMBL1302661 0.89 NOX4 (0.53) NOX4CYBBCYP3A4NOX1
SCHEMBL1302779 0.89 NOX4 (0.62) NOX4CYBBCYP3A4NOX1
SCHEMBL1303036 0.88 NOX4 (0.58) NOX4CYBBCYP3A4NOX1
SCHEMBL3611116 0.88 NOX4 (0.67) NOX4CYBB
SCHEMBL1302709 0.87 NOX4 (0.61) NOX4CYBBCYP2A13
SCHEMBL1302720 0.87 NOX4 (0.56) NOX4CYBBCYP3A4NOX1CYP2A13
SCHEMBL1303271 0.87 NOX4 (0.68) NOX4CYBBCYP3A4NOX1
SCHEMBL1303132 0.86 NOX4 (0.54) NOX4CYBBCYP3A4NOX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342203-B1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2015-11-04 EP claimed
US-9006238-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2015-04-14 US claimed
US-20130158027-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2013-06-20 US claimed
US-8455486-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2013-06-04 US claimed
US-20110178082-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2011-07-21 US claimed
EP-2342203-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GenKyoTex SA (CH) 2011-07-13 EP claimed
WO-2010035220-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2010-04-01 WO claimed
EP-2166009-A1 Pyrazolo pyridine derivatives as nadph oxidase inhibitors GENKYO TEX SA (CH) 2010-03-24 EP claimed
EP-2342203-B1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2015-11-04 EP disclosed
US-9006238-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2015-04-14 US disclosed
US-20130158027-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2013-06-20 US disclosed
US-8455486-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2013-06-04 US disclosed
US-20110178082-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2011-07-21 US disclosed
EP-2166009-A1 Pyrazolo pyridine derivatives as nadph oxidase inhibitors GENKYO TEX SA (CH) 2010-03-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158027-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS NOX1, NOX4, CYBB NOX4 2/4885CYBB 3/4885CYP3A4 157/4885
US-20110178082-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS NOX1, NOX4, CYBB NOX4 2/4885CYBB 3/4885CYP3A4 157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.